Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease: A Focus on Early Phase Clinical Drug Development (Hardcover, 2, 2019)

Part 1: Review of Clinical Investigative Methods Chapter 1: Quantifying Insulin Action in Humans Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins Chapter 4: Measurement of Energy Expenditure Chapter 5: QUANTIFYING APPETITE AND SATIETY Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH Chapter 12: Omics: Potential role in early phase drug development Part 2: Preclinical Drug Development and Transitioning to Clinical Studies Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS - CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research: An Overview Chapter 18: Transitioning from Preclinical to Clinical Drug Development Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders Chapter 20: Early Phase Metabolic Research with Reference to Special Populations